Working Group XIII – Real-World Data and Real-World Evidence in Regulatory Decision Making
There is increasing interest in the use of Real-World data (RWD) to support regulatory decision making across the product life cycle. Key sources of RWD are electronic health records, claims data, prescription data, and patient registries. Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from an analysis of RWD. For decades, such evidence has been well accepted for satisfying post-approval safety monitoring requirements but has not been used commonly to demonstrate drug effectiveness, which is a relatively new concept.
As applications are increasing, it is proposed that CIOMS develop a consensus report and recommendations for the use of RWD and RWE in regulatory decision-making related to biopharmaceutical products. This report will cover three key areas:
- Articulate the different RWD/RWE requirements depending on the intent of use e.g. Regulatory, Payers, and Public Health;
- Propose harmonized practices and guidance for using RWD and RWE for regulatory purposes (given that there are no existing consensus guidelines);
- Articulate point of view (POV) on key ethical issues relevant to RWD and RWE and a provisional set of standards to address those issues (the high-level POV may lead to a separate/satellite group of ethicists to deal with it).
Working Group objectives
The CIOMS guidance would create a reference worldwide for researchers and regulators involved in RWD/RWE studies, as well as pharmaceutical and biotechnology companies involved in product development and marketing.
The primary remit of the proposed CIOMS WG would be to develop, for global use, a consensus report and recommendations on principles to be applied regarding triggers, objectives, research questions, design features, and timing of RWD and RWE as part of the regulatory process for products in the peri-approval stage of development or for authorized products.
The working group would also be expected to evaluate the increasingly novel methodologies that are being used to design studies, collect and analyse data, and use the output in the regulatory process to assess how RWE can contribute to effectiveness decisions.
Supporting this, the proposed CIOMS WG would recommend an approach and prepare a consensus report promoting harmonization across global drug regulatory authorities and develop a POV on ethical considerations and challenges related to RWD and RWE.
- 1st meeting held on 30 March 2020 (virtual meeting) (Minutes)
- 2nd meeting to be held on 29 June 2020 (virtual meeting)
- 3rd meeting to be held on 23-24 September 2020 in Geneva, Switzerland
The Working Group (WG) makes minutes of its in person and virtual meetings public. Persons and parties not part of the Working Group (WG) are welcome to give their feedback on the WG work by sending their input to email@example.com
CIOMS Working Groups usually take 2-4 years to finalize their consensus document and recommendations. Most groups hold two in-person meetings per year, with telework in between. The groups make use of collaborative efforts and capitalize on existing initiatives in order to provide output that is as comprehensive as possible, does not duplicate other efforts and has added value.
20 - 21 October 2020
7th Meeting Working Group XI Patient Involvement in Development/Safe Use Medicines
23 - 24 September 2020
3rd Meeting Working Group XIII Real-World Data & Evidence in Regulatory Decision-Making
08 - 09 September 2020
Peapack, New Jersey, USA
3rd meeting of WG XII Benefit-Risk Balance for Medicinal Products
25 - 26 August 2020
3rd meeting of MedDRA Labelling Groupings Working Group
20 - 21 August 2020
8th meeting of Clinical Research in Resource-Limited Settings Working Group
29 June 2020
2nd Meeting Working Group XIII Real-World Data & Evidence in Regulatory Decision-Making
26 June 2020
6th Meeting Working Group XI Patient Involvement in Development/Safe Use Medicines
22 June 2020